相似文献
1
Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination.
Cold Spring Harb Perspect Biol. 2018 Jun 1;10(6):a028811. doi: 10.1101/cshperspect.a028811.
2
Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003.
Front Immunol. 2019 Jul 31;10:1778. doi: 10.3389/fimmu.2019.01778. eCollection 2019.
3
Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
Hum Vaccin Immunother. 2019;15(10):2328-2336. doi: 10.1080/21645515.2019.1643676. Epub 2019 Aug 23.
4
Human CD4 T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity.
J Virol. 2017 Feb 14;91(5). doi: 10.1128/JVI.02147-16. Print 2017 Mar 1.
5
The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Asian Pac J Allergy Immunol. 2015 Sep;33(3):182-8. doi: 10.12932/AP0508.33.3.2015.
6
Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.
Cold Spring Harb Perspect Biol. 2018 Jun 1;10(6):a029371. doi: 10.1101/cshperspect.a029371.
7
Dengue vaccine candidates in development.
Curr Top Microbiol Immunol. 2010;338:129-43. doi: 10.1007/978-3-642-02215-9_10.
8
Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vaccine.
Cold Spring Harb Perspect Biol. 2018 Jun 1;10(6):a029462. doi: 10.1101/cshperspect.a029462.
9
Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.
J Infect Dis. 2011 Feb 1;203(3):327-34. doi: 10.1093/infdis/jiq059. Epub 2010 Dec 14.
10
Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Hum Vaccin Immunother. 2014;10(10):2853-63. doi: 10.4161/21645515.2014.972131.
引用本文的文献
1
Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses.
Front Immunol. 2023 Aug 15;14:1208041. doi: 10.3389/fimmu.2023.1208041. eCollection 2023.
2
Recent Advancements in Mosquito-Borne Flavivirus Vaccine Development.
Viruses. 2023 Mar 23;15(4):813. doi: 10.3390/v15040813.
3
An intermolecular-split G-quadruplex DNAzyme sensor for dengue virus detection.
RSC Adv. 2020 Sep 7;10(55):33040-33051. doi: 10.1039/d0ra05439a.
4
Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
Hum Vaccin Immunother. 2019;15(10):2328-2336. doi: 10.1080/21645515.2019.1643676. Epub 2019 Aug 23.
5
Dengue-specific CD8+ T cell subsets display specialized transcriptomic and TCR profiles.
J Clin Invest. 2019 Mar 18;129(4):1727-1741. doi: 10.1172/JCI123726.
6
Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development.
PLoS Negl Trop Dis. 2019 Jan 17;13(1):e0006919. doi: 10.1371/journal.pntd.0006919. eCollection 2019 Jan.
7
Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice.
EXCLI J. 2018 Nov 5;17:1054-1068. doi: 10.17179/excli2018-1664. eCollection 2018.
8
A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates.
Cell Rep. 2018 Nov 6;25(6):1385-1394.e7. doi: 10.1016/j.celrep.2018.10.031.
9
Dengue envelope-based 'four-in-one' virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice.
Sci Rep. 2018 Jun 5;8(1):8643. doi: 10.1038/s41598-018-26904-5.
10
Biomimetic inorganic camouflage circumvents antibody-dependent enhancement of infection.
Chem Sci. 2017 Dec 1;8(12):8240-8246. doi: 10.1039/c7sc03868b. Epub 2017 Oct 20.
本文引用的文献
1
Dengue Vaccine Efficacy: Not a Zero Sum Game.
J Infect Dis. 2016 Dec 15;214(12):2014. doi: 10.1093/infdis/jiw458. Epub 2016 Sep 29.
2
Dengue infection.
Nat Rev Dis Primers. 2016 Aug 18;2:16055. doi: 10.1038/nrdp.2016.55.
3
Population Perspectives and World Health Organization Recommendations for CYD-TDV Dengue Vaccine.
J Infect Dis. 2016 Dec 15;214(12):1796-1799. doi: 10.1093/infdis/jiw341. Epub 2016 Aug 5.
4
Dengue vaccine: WHO position paper – July 2016.
Wkly Epidemiol Rec. 2016 Jul 29;91(30):349-64.
5
A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.
J Infect Dis. 2016 Sep 15;214(6):832-5. doi: 10.1093/infdis/jiw067. Epub 2016 Feb 16.
6
Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.
Nat Rev Microbiol. 2016 Jan;14(1):45-54. doi: 10.1038/nrmicro.2015.2. Epub 2015 Dec 7.
7
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.
N Engl J Med. 2015 Sep 24;373(13):1195-206. doi: 10.1056/NEJMoa1506223. Epub 2015 Jul 27.
8
Trials and tribulations on the path to developing a dengue vaccine.
Vaccine. 2015 Nov 27;33 Suppl 4:D24-31. doi: 10.1016/j.vaccine.2015.05.095. Epub 2015 Jun 27.
9
Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.
J Infect Dis. 2015 Sep 1;212(5):702-10. doi: 10.1093/infdis/jiv082. Epub 2015 Mar 22.
10
The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.
J Virol. 2015 Jan;89(1):120-8. doi: 10.1128/JVI.02129-14. Epub 2014 Oct 15.
Zotero 插件